Association of Proton Pump Inhibitors With Risk of Der

JAMA Neurology 73, 410

DOI: 10.1001/jamaneurol.2015.4791

Citation Report

#	Article	IF	CITATIONS
2	The Indications, Applications, and Risks of Proton Pump Inhibitors. Deutsches Ärzteblatt International, 2016, 113, 477-83.	0.6	61
3	Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clinical and Experimental Gastroenterology, 2016, Volume 9, 163-172.	1.0	8
4	The possible risks of proton pump inhibitors. Medical Journal of Australia, 2016, 205, 292-293.	0.8	9
5	Proton pump inhibitor use may increase dementia risk. Pharmacy Today, 2016, 22, 20.	0.0	O
6	Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 445-460.	8.2	82
7	Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 2016, 14, 179.	2.3	300
8	Clarifying dementia risk factors: treading in murky waters. International Psychogeriatrics, 2016, 28, 1057-1058.	0.6	0
9	Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open, 2016, 6, e012177.	0.8	46
10	The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole- ¹³ C breath test in GERD patients: clinical relevance for personalized medicine. Journal of Breath Research, 2016, 10, 046017.	1.5	12
11	Gastric acid secretion. Current Opinion in Gastroenterology, 2016, 32, 452-460.	1.0	40
12	Long-Term PPI Use: Balancing Potential Harms and Documented Benefits. American Journal of Gastroenterology, 2016, 111, 913-915.	0.2	40
13	Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1345-1352.	2.5	71
14	Do proton pump inhibitors cause dementia?. Geriatric Nursing, 2016, 37, 228-229.	0.9	2
15	Proton Pump Inhibitors Accelerate Endothelial Senescence. Circulation Research, 2016, 118, e36-42.	2.0	112
16	Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. Journal of Molecular Psychiatry, 2016, 4, 3.	2.0	28
19	A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimer's Research and Therapy, 2016, 8, 33.	3.0	11
20	Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. New England Journal of Medicine, 2016, 375, 1197-1198.	13.9	9
21	Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness. Journal of Clinical Pharmacology, 2016, 56, 1500-1506.	1.0	23

#	ARTICLE	IF	Citations
22	Can Endothelial Injury Provide the Passage to Explain the Vascular Effects of Proton Pump Inhibitors?. Circulation Research, 2016, 118, 1858-1860.	2.0	3
23	Enteroviral Postencephalitic Parkinsonism With Evidence of Impaired Presynaptic Dopaminergic Function. JAMA Neurology, 2016, 73, 1023.	4.5	4
24	A Matched Comparison of Per Oral Endoscopic Myotomy to Laparoscopic Heller Myotomy in the Treatment of Achalasia. Journal of Gastrointestinal Surgery, 2016, 20, 1789-1796.	0.9	69
25	Treating Pediatric Obstructive Sleep Apnea. Do We Have The Data?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 656-658.	2.5	1
26	Gastrointestinal manifestations of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 247-256.	1.0	106
28	Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples. Pharmacology, 2016, 98, 70-72.	0.9	2
29	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1025.	4.5	1
30	Proton Pump Inhibitors and Dementia Incidence—Reply. JAMA Neurology, 2016, 73, 1028.	4.5	1
31	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1027.	4.5	1
32	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1025.	4.5	2
33	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1026.	4.5	2
34	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1026.	4.5	1
35	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1027.	4.5	1
36	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1026.	4.5	1
37	Are proton pump inhibitors really so dangerous?. Digestive and Liver Disease, 2016, 48, 851-859.	0.4	66
39	Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. New England Journal of Medicine, 2016, 374, 2367-2376.	13.9	78
40	Risks associated with chronic PPI use $\hat{a}\in$ " signal or noise?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 253-254.	8.2	23
41	Do Proton Pump Inhibitors Increase the Risk of Dementia?. JAMA Neurology, 2016, 73, 379.	4. 5	27

#	ARTICLE	IF	CITATIONS
43	An Ecological Approach to Reducing Potentially Inappropriate Medication Use: Canadian Deprescribing Network. Canadian Journal on Aging, 2017, 36, 97-107.	0.6	52
44	Adverse Drug Reactions Associated With Cholinesterase Inhibitorsâ€"Sequence Symmetry Analyses Using Prescription Claims Data. Journal of the American Medical Directors Association, 2017, 18, 186-189.	1.2	6
45	Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention. Current Problems in Cardiology, 2017, 42, 146-164.	1.1	51
47	Proton pump inhibitors: Risks of longâ€ŧerm use. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1295-1302.	1.4	144
48	Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1426-1435.	1.4	46
49	Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Current Treatment Options in Gastroenterology, 2017, 15, 1-9.	0.3	39
50	Proton Pump Inhibitors and Kidney Diseaseâ€"GI Upset for the Nephrologist?. Kidney International Reports, 2017, 2, 297-301.	0.4	24
51	Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults. Drugs and Aging, 2017, 34, 265-287.	1.3	33
52	The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs, 2017, 77, 547-561.	4.9	62
53	The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology, 2017, 152, 706-715.	0.6	572
54	Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases. Seminars in Cancer Biology, 2017, 43, 157-179.	4.3	59
55	Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs. Clinical Therapeutics, 2017, 39, 404-427.e36.	1.1	7
56	Lower Esophageal Sphincter Augmentation for Gastroesophageal Reflux Disease: The Safety of a Modern Implant. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 586-591.	0.5	43
57	Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. Expert Review of Clinical Pharmacology, 2017, 10, 875-888.	1.3	11
58	Impact of A Collaborative Strategy to Reduce the Inappropriate Use of Acid Suppressive Therapy in Non–Intensive Care Unit Patients. Annals of Pharmacotherapy, 2017, 51, 577-583.	0.9	5
59	Outcomes of magnetic sphincter augmentation - A community hospital perspective. American Journal of Surgery, 2017, 213, 1019-1023.	0.9	18
60	Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients. Journal of the American Heart Association, 2017, 6 , $.$	1.6	23
61	Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Scientific Reports, 2017, 7, 2871.	1.6	15

#	ARTICLE	IF	Citations
62	Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia. Journal of the American Geriatrics Society, 2017, 65, 1969-1974.	1.3	93
63	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
64	Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet, The, 2017, 390, 490-499.	6.3	290
65	Preventing major gastrointestinal bleeding in elderly patients. Lancet, The, 2017, 390, 435-437.	6.3	5
66	Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2985-2993.	1.8	17
67	Paired editorial: Do sleeve gastrectomy and gastric bypass influence treatment with proton pump inhibitors 4 years postsurgery? A nationwide cohort. Surgery for Obesity and Related Diseases, 2017, 13, 960-961.	1.0	0
68	Common Drug Side Effects and Drugâ€Drug Interactions in Elderly Adults in Primary Care. Journal of the American Geriatrics Society, 2017, 65, 1578-1585.	1.3	29
69	Pharmacoepidemiology for nephrologists: do proton pump inhibitors cause chronic kidney disease?. Nephrology Dialysis Transplantation, 2017, 32, ii40-ii46.	0.4	8
70	GERD Management. American Journal of Lifestyle Medicine, 2017, 11, 24-28.	0.8	2
71	The epidemiology of <i>Clostridium difficile</i> infection in a national kidney transplant center. Clinical Transplantation, 2017, 31, e12962.	0.8	2
72	Recent advances in diagnostic testing for gastroesophageal reflux disease. Expert Review of Gastroenterology and Hepatology, 2017, 11, 531-537.	1.4	8
73	Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients. Journal of the American Geriatrics Society, 2017, 65, 1441-1447.	1.3	23
74	Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 2498-2508.	1.3	47
75	The Quality of Care for Gastroesophageal Reflux Disease. Digestive Diseases and Sciences, 2017, 62, 569-576.	1.1	13
76	Lung disease severity in idiopathic pulmonary fibrosis is more strongly associated with impedance measures of bolus reflux than pH parameters of acid reflux alone. Neurogastroenterology and Motility, 2017, 29, e13001.	1.6	23
77	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 11-16.	0.6	68
78	The effect of pharmacists on ward rounds measured by the STOPP/START tool in a specialized geriatric unit. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 178-184.	0.7	11
79	Gastroesophageal Reflux in Children. , 2017, , .		2

#	Article	IF	CITATIONS
80	"First Do No Harm― Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. Digestive Diseases and Sciences, 2017, 62, 2947-2951.	1.1	0
81	GER and Antacid Medications. , 2017, , 321-335.		0
82	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
83	Do Acid-Suppressing Medications in Inflammatory Bowel Disease Increase Risk for Flare?. Digestion, 2017, 95, 186-187.	1.2	4
84	Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics. Annals of Pharmacotherapy, 2017, 51, 848-854.	0.9	11
86	Proton-pump inhibitors: understanding the complications and risks. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 697-710.	8.2	196
87	Acupuncture and related therapies used as add-on or alternative to prokinetics for functional dyspepsia: overview of systematic reviews and network meta-analysis. Scientific Reports, 2017, 7, 10320.	1.6	35
88	A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1023.	1.2	81
89	Association Between Proton Pump Inhibitor Use and Cognitive Function in Women. Gastroenterology, 2017, 153, 971-979.e4.	0.6	70
90	Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Therapeutic Advances in Drug Safety, 2017, 8, 273-297.	1.0	149
91	Proton Pump Inhibitors and Chronic Kidney Disease: CausationÂor Another False Alarm?. Gastroenterology, 2017, 153, 638-640.	0.6	2
92	Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Scientific Reports, 2017, 7, 5527.	1.6	34
93	PPIs and hypomagnesaemia: more common than we thought?. The Prescriber, 2017, 28, 50-51.	0.1	0
94	Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Current Gastroenterology Reports, 2017, 19, 46.	1.1	33
95	Aspirin in the elderly â€" tailored approaches ahead?. Nature Reviews Cardiology, 2017, 14, 571-572.	6.1	1
96	Proton Pump Inhibitors and Dementia: Deciphering the Data. American Journal of Gastroenterology, 2017, 112, 1809-1811.	0.2	9
97	Medication Review and the Active Consumer of Health. Holistic Nursing Practice, 2017, 31, 357-357.	0.3	0
98	Proton pump inhibitors and the risk of severe cognitive impairment: TheÂrole of posttraumatic stress disorder. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 579-583.	1.8	9

#	ARTICLE	IF	Citations
99	No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. American Journal of Gastroenterology, 2017, 112, 1802-1808.	0.2	69
100	Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open, 2017, 7, e015735.	0.8	194
102	Proton Pump Inhibitors and Risk of Rhabdomyolysis. Drug Safety, 2017, 40, 61-64.	1.4	20
103	Fundoplication for Gastroesophageal Reflux Disease: Tips for Success. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 1-5.	0.5	5
104	Appropriateness of Acid Suppression Therapy. Annals of Pharmacotherapy, 2017, 51, 125-134.	0.9	10
105	Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2017, 15, 214-221.e2.	2.4	59
106	Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. American Journal of Gastroenterology, 2017, 112, 95-101.	0.2	62
107	Longâ€term use of proton pump inhibitors and prevalence of diseaseâ€and drugâ€related reasons for gastroprotectionâ€"a crossâ€sectional populationâ€based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 9-16.	0.9	54
108	Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology, 2017, 152, 134-141.	0.6	133
109	A Mixed-Methods Study of Patient Views on Reflux Symptoms and Medication Routines. Journal of Voice, 2017, 31, 381.e15-381.e25.	0.6	24
111	182An Audit of Appropriate Proton Pump Inhibitor Prescribing in an Older Inpatient Cohort. Age and Ageing, 2017, 46, iii13-iii59.	0.7	0
113	Gastrointestinal Drugs. Side Effects of Drugs Annual, 2017, 39, 373-387.	0.6	2
114	Autophagy and Proteostasis: A Unifying Theory of ÂNeurodegenerative Disease. Journal of Restorative Medicine, 2017, 6, 3-18.	0.7	0
115	Gastrointestinal Involvement in Systemic Sclerosis. Handbook of Systemic Autoimmune Diseases, 2017, , 243-261.	0.1	0
116	Quantifying Laryngopharyngeal Reflux in Singers: Perceptual and Objective Findings. BioMed Research International, 2017, 2017, 1-10.	0.9	6
117	Proton-Pump Inhibitors and Risk of Dementia. The Consultant Pharmacist, 2017, 32, 682-686.	0.4	2
118	Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS ONE, 2017, 12, e0171006.	1.1	66
119	Drug discovery. , 2017, , 183-279.		1

#	Article	IF	Citations
120	Proton pump inhibitors in liver cirrhosis: a review of benefits and harms. AME Medical Journal, 2017, , 36-36.	0.4	4
121	Critical Care Pharmacists and Medication Management in an ICU Recovery Center. Annals of Pharmacotherapy, 2018, 52, 713-723.	0.9	50
122	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology and Hepatology, 2018, 3, 231-241.	3.7	156
123	External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients. Stroke, 2018, 49, 601-606.	1.0	13
124	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Current Atherosclerosis Reports, 2018, 20, 15.	2.0	5
125	Clinical Practice Guideline: Hoarseness (Dysphonia) (Update). Otolaryngology - Head and Neck Surgery, 2018, 158, S1-S42.	1.1	189
126	Side Effects of Longâ€Term Proton Pump Inhibitor Use: A Review. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 114-121.	1.2	105
127	Proton pump inhibitor use and cancer mortality. International Journal of Cancer, 2018, 143, 1315-1326.	2.3	37
128	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 447-460.	1.5	144
130	Lack of Association Between Proton Pump Inhibitor Use andÂCognitive Decline. Clinical Gastroenterology and Hepatology, 2018, 16, 681-689.	2.4	32
131	Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clinic Proceedings, 2018, 93, 240-246.	1.4	173
132	Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis. Gastroenterology, 2018, 154, 1298-1308.e7.	0.6	121
133	The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013. Drug Safety, 2018, 41, 615-624.	1.4	23
134	The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 331-342.	0.4	117
139	Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria. Digestive Diseases and Sciences, 2018, 63, 881-889.	1.1	15
140	Lack of proton pump inhibitor trial prior to commencing therapy for eosinophilic esophagitis is common in the community. Ecological Management and Restoration, 2018, 31, .	0.2	3
141	The Effects of Reflux on the Elderly. Otolaryngologic Clinics of North America, 2018, 51, 779-787.	0.5	17
142	Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapie, 2018, 73, 385-388.	0.6	14

#	Article	IF	CITATIONS
143	Practice Patterns of Referring Physicians in Management of the Dysphonic Patient. Otolaryngology - Head and Neck Surgery, 2018, 158, 1072-1078.	1.1	8
144	Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?. American Journal of Gastroenterology, 2018, 113, 519-528.	0.2	39
145	Evidence-based deprescribing of proton pump inhibitors in long-term care. Research in Social and Administrative Pharmacy, 2018, 14, 124-126.	1.5	4
147	Weaning of proton pump inhibitors in patients with suspected laryngopharyngeal reflux disease. Laryngoscope, 2018, 128, 133-137.	1.1	22
148	Treating laryngopharyngeal reflux: Evaluation of an anti-reflux program with comparison to medications. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2018, 39, 50-55.	0.6	27
149	Anterior Versus Posterior Fundoplication, Are They Equal?. , 2018, , 93-104.		O
150	I Am Tired of Taking Pills for My Reflux, What Else Can I Do? Surgical and Endoscopic Treatment for GERD. , 2018, , 143-152.		0
151	Use of proton-pump inhibitors is associated with depression: a population-based study. International Psychogeriatrics, 2018, 30, 153-159.	0.6	44
152	Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis. Therapie, 2018, 73, 273-281.	0.6	15
153	Gastrointestinal Involvement in Systemic Sclerosis. Journal of Clinical Rheumatology, 2018, 24, 328-337.	0.5	50
154	Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function. Journal of Clinical Gastroenterology, 2018, 52, 691-695.	1.1	2
155	Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from <scp>ERCHIVES</scp> . Alimentary Pharmacology and Therapeutics, 2018, 47, 246-258.	1.9	42
156	Proton Pump Inhibitor Use and Dementia Risk: Prospective Populationâ€Based Study. Journal of the American Geriatrics Society, 2018, 66, 247-253.	1.3	57
157	Proton Pump Inhibitor Therapy and Dementia: What Is the Evidence?. Journal of the American Geriatrics Society, 2018, 66, 224-226.	1.3	3
158	Evaluation of Prescribing Appropriateness and Initiatives to Improve Prescribing of Proton Pump Inhibitors at Vancouver General Hospital. Canadian Journal of Hospital Pharmacy, 2018, 71, .	0.1	3
159	Internists' Perceptions of Proton Pump Inhibitor Adverse Effects and Impact on Prescribing Practices: Results of a Nationwide Survey. Gastroenterology Research, 2018, 11, 11-17.	0.4	8
160	Association between the Use of Proton Pump Inhibitors and Cognitive Impairment in Older Adults. Revista Universitas Medica, 2018, 60, .	0.0	0
161	Safety assessment of omeprazole use: a review. Sao Paulo Medical Journal, 2018, 136, 557-570.	0.4	7

#	Article	IF	CITATIONS
163	Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1395-1405.	0.8	64
164	Evidence-based medication review in care homes. Nursing and Residential Care, 2018, 20, 32-36.	0.1	1
165	Current Trends in the Management of Gastroesophageal Reflux Disease. Gut and Liver, 2018, 12, 7-16.	1.4	147
166	Principles of Geriatric Pharmacotherapy. , 0, , 28-50.		3
167	Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 1116.	1.2	18
168	Proton Pump Inhibitors and the Risk of Dementia: Is There a Link?. Medical Principles and Practice, 2018, 27, 585-585.	1.1	0
169	Proton Pump Inhibitors: Are They a Real Threat to the Patient?. GE Portuguese Journal of Gastroenterology, 2018, 25, 243-252.	0.3	5
170	ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. Journal of Veterinary Internal Medicine, 2018, 32, 1823-1840.	0.6	77
171	Families in the Intensive Care Unit., 2018,,.		9
172	Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investigative Otolaryngology, 2018, 3, 457-462.	0.6	21
173	Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. PLoS ONE, 2018, 13, e0203878.	1.1	20
174	Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin. Nature Reviews Clinical Oncology, 2018, 15, 728-730.	12.5	1
175	Strategies for Effective Discontinuation of Proton Pump Inhibitors. Current Gastroenterology Reports, 2018, 20, 27.	1.1	18
176	Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plasticity, 2018, 2018, 1-9.	1.0	56
177	Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. Journal of Neurogastroenterology and Motility, 2018, 24, 182-196.	0.8	155
178	Gaviscon \hat{A}^{\odot} Advance alone versus co-prescription of Gaviscon \hat{A}^{\odot} Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2515-2521.	0.8	37
179	A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety, 2018, 17, 785-794.	1.0	24
180	Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutrition in Clinical Practice, 2018, 33, 614-624.	1.1	46

#	Article	IF	Citations
181	Pseudotumor Cerebri and Glymphatic Dysfunction. Frontiers in Neurology, 2017, 8, 734.	1.1	27
182	Editorial: proton pump inhibitors (<scp>PPI</scp> s) and primary liver cancer. Alimentary Pharmacology and Therapeutics, 2018, 48, 380-381.	1.9	0
183	Gastroesophageal Reflux Characteristics and Patterns in Patients with Idiopathic Subglottic Stenosis. Gastroenterology Research and Practice, 2018, 2018, 1-5.	0.7	7
184	A Nationwide Population-Based Cohort Study of Dementia Risk Among Acid Suppressant Users. American Journal of Geriatric Psychiatry, 2018, 26, 1175-1183.	0.6	24
186	Reply to: Association Between Proton Pump Inhibitors and Alzheimer's Disease in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 1850-1850.	1.3	0
187	Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case–Control Analysis. Drug Safety, 2018, 41, 1387-1396.	1.4	31
188	Association Between Proton Pump Inhibitor Use and Alzheimer's Disease in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 1848-1850.	1.3	7
189	Do recent reports about the adverse effects of proton pump inhibitors change providers' prescription practice?. Ecological Management and Restoration, 2018, 31, .	0.2	3
190	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. , 2018, , 197-288.		0
191	Dysbiosis of the Microbiota: Therapeutic Strategies Utilizing Dietary Modification, Pro- and Prebiotics and Fecal Transplant Therapies in Promoting Normal Balance and Local GI Functions., 2018,, 381-419.		3
192	Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial). Digestive Diseases and Sciences, 2019, 64, 158-166.	1,1	13
193	Association between polypharmacy and dementia – A systematic review and metaanalysis. Aging and Mental Health, 2019, 23, 932-941.	1.5	44
194	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2019, 157, 682-691.e2.	0.6	299
195	Proton pump inhibitor use does not increase dementia and Alzheimer's disease risk: An updated meta-analysis of published studies involving 642305 patients. PLoS ONE, 2019, 14, e0219213.	1.1	22
196	La búsqueda del Grial: una carrera por la supresión ácida. Revista De GastroenterologÃa De México, 2019, 84, 344-356.	0.4	0
197	The Approach to a Patient with Suspected Laryngopharyngeal Reflux Disease (LPRD)., 2019,, 13-31.		0
198	Adverse Effects of Proton Pump Inhibitorsâ€"Evidence and Plausibility. International Journal of Molecular Sciences, 2019, 20, 5203.	1.8	92
199	Pharmacological signatures of the reduced incidence and the progression of cognitive decline in ageing populations suggest the protective role of beneficial polypharmacy. PLoS ONE, 2019, 14, e0224315.	1.1	6

#	Article	IF	CITATIONS
200	Problems Associated with Deprescribing of Proton Pump Inhibitors. International Journal of Molecular Sciences, 2019, 20, 5469.	1.8	51
201	Laparoscopic Hiatal Hernia Repair Followed by Transoral Incisionless Fundoplication With EsophyX Device (HH + TIF): Efficacy and Safety in Two Community Hospitals. Surgical Innovation, 2019, 26, 675-686.	0.4	43
202	Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety, 2019, 18, 1043-1053.	1.0	44
203	In search of the grail: A race for acid suppression. Revista De GastroenterologÃa De México (English) Tj ETQq1 1	0.784314 0.1	1 _{[gBT} /Ove
204	PPI Long Term Use: Risk of Neurological Adverse Events?. Frontiers in Neurology, 2019, 9, 1142.	1.1	28
205	Drug interactions with dementiaâ€related pathophysiological pathways worsen or prevent dementia. British Journal of Pharmacology, 2019, 176, 3413-3434.	2.7	9
206	Medical Management of GERD., 2019, , 147-160.		2
207	Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2135-2143.	1.4	13
208	Laryngopharyngeal Reflux Disease., 2019,,.		3
209	Eosinophilic Esophagitis Is Rarely Continually Symptomatic 10ÂYears After an Initial Treatment Course in Adults. Digestive Diseases and Sciences, 2019, 64, 3568-3578.	1.1	4
210	The association of vascular disorders with incident dementia in different age groups. Alzheimer's Research and Therapy, 2019, 11, 47.	3.0	19
211	Inappropriate Prescribing to Elderly Patients in an Internal Medicine Ward. Acta Medica Portuguesa, 2019, 32, 141-148.	0.2	8
212	The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety, 2019, 10, 204209861880992.	1.0	129
213	Quality of Life 10 Years after Sleeve Gastrectomy: A Multicenter Study. Obesity Facts, 2019, 12, 157-166.	1.6	29
214	Proton pump inhibitor use and risk of dementia. Medicine (United States), 2019, 98, e14422.	0.4	42
215	Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European Heart Journal, 2019, 40, 1963-1970.	1.0	56
216	Does Longâ€Term Proton Pump Inhibitor Use Increase Risk of Dementia? Not Really! Results of the Groupâ€Based Trajectory Analysis. Clinical Pharmacology and Therapeutics, 2019, 106, 616-622.	2.3	18
217	JAMA Neurology—The Year in Review, 2018. JAMA Neurology, 2019, 76, 398.	4.5	O

#	Article	IF	CITATIONS
218	The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. Drugs, 2019, 79, 715-731.	4.9	29
219	Implementing a Systematic Approach to Deprescribing Proton Pump Inhibitor Therapy in Older Adults. , 2019, 34, 47-55.		7
220	Gastroesophageal Reflux Disease. Gastroenterology Nursing, 2019, 42, 20-28.	0.2	59
221	Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Scientific Reports, 2019, 9, 2282.	1.6	48
222	Statewide Analysis of Peptic Ulcer Disease: As Hospitalizations Decrease, Procedural Volume Remains Steady. American Surgeon, 2019, 85, 1028-1032.	0.4	4
223	Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Scientific Reports, 2019, 9, 17280.	1.6	42
224	The Phylogeny and Biological Function of Gastric Juice—Microbiological Consequences of Removing Gastric Acid. International Journal of Molecular Sciences, 2019, 20, 6031.	1.8	45
225	Evaluation of Medication Errors at the Transition of Care From an ICU to Non-ICU Location. Critical Care Medicine, 2019, 47, 543-549.	0.4	50
226	Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. Current Gastroenterology Reports, 2019, 21, 65.	1.1	13
227	Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study. Therapie, 2019, 74, 507-512.	0.6	8
228	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology, 2019, 69, 1151-1164.	3.6	22
229	Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis. Life Sciences, 2019, 218, 213-223.	2.0	54
230	Pediatricians' proficiency in the care of the dysphonic child. Laryngoscope, 2019, 129, 1756-1762.	1.1	7
231	Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?. Trends in Cardiovascular Medicine, 2019, 29, 353-360.	2.3	13
232	Associated risks of proton pump inhibitors and their influence on prescribing habits: is change truly warranted?. Ecological Management and Restoration, 2019, 32, .	0.2	0
233	Management of gastroesophageal reflux disease. Disease-a-Month, 2020, 66, 100849.	0.4	12
234	Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. American Journal of Kidney Diseases, 2020, 75, 497-507.	2.1	86
235	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 57-68.	1.4	13

#	ARTICLE	IF	Citations
236	No association between proton pump inhibitor use and risk of dementia: Evidence from a metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 19-28.	1.4	24
237	Acid Suppressive Therapy. , 2020, , 18-31.		0
238	Chronic Kidney Disease and Gastrointestinal Disorders. , 2020, , 521-539.		6
239	Suitability of patient education materials on proton-pump inhibitors deprescribing: a focused review. European Journal of Clinical Pharmacology, 2020, 76, 17-21.	0.8	5
240	Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?. Alimentary Pharmacology and Therapeutics, 2020, 51, 121-128.	1.9	24
241	Utilization of Medications With Cognitive Impairment Side Effects and the Implications for Older Adults' Cognitive Function. Journal of Aging and Health, 2020, 32, 1165-1177.	0.9	8
242	The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. International Journal of Neuroscience, 2020, 130, 727-735.	0.8	14
243	Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. European Journal of Clinical Pharmacology, 2020, 76, 139-147.	0.8	28
244	No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies. American Journal of Gastroenterology, 2020, 115, 671-678.	0.2	27
245	The analysis of the use of potentially inappropriate medications in elderly in the Slovak Republic. International Journal of Clinical Pharmacy, 2020, 42, 100-109.	1.0	8
246	Foregut Surgery., 2020,,.		2
247	Controversies Around Measuring Drug Toxicity: US Food and Drug Administration and Gastrointestinal Perspectives. Gastroenterology, 2020, 158, 22-27.	0.6	2
248	Failed Swallows on High-Resolution Manometry Independently Correlates With Severity of LPR Symptoms. Journal of Voice, 2022, 36, 832-837.	0.6	4
249	Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index. Biochemical Pharmacology, 2020, 182, 114212.	2.0	7
250	Priorities for intervention of childhood stunting in northeastern Ethiopia:ÂA matched case-control study. PLoS ONE, 2020, 15, e0239255.	1.1	6
251	Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants. Digestive Diseases and Sciences, 2021, 66, 3476-3481.	1.1	4
252	The evolution of TIF: transoral incisionless fundoplication. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092420.	1.4	25
253	Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: A meta-analysis study. Medical Hypotheses, 2020, 144, 109989.	0.8	5

#	Article	IF	CITATIONS
254	Who Needs Gastroprotection in 2020?. Current Treatment Options in Gastroenterology, 2020, 18, 557-573.	0.3	11
255	Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian Journal of Gastroenterology, 2020, 39, 591-598.	0.7	3
256	Patient Awareness of Reported Adverse Effects Associated with Proton Pump Inhibitors in a Medically Underserved Community. Healthcare (Switzerland), 2020, 8, 499.	1.0	4
257	Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12095.	1.8	10
258	Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 8271.	1.2	17
259	Potential proton pump inhibitor–related adverse effects. Annals of the New York Academy of Sciences, 2020, 1481, 43-58.	1.8	24
260	Drawbacks of the Current Algorithm for Patients With Symptoms of Gastroesophageal Reflux Disease and the Impact of Adding Wireless pH Study to the Initial Diagnostic Endoscopy: Data From High-Volume Rural Antireflux Center. American Surgeon, 2020, 86, 422-428.	0.4	4
261	Baseline Prevalence of Polypharmacy in Older Hypertensive Study Subjects with Elevated Dementia Risk: Findings from the Risk Reduction for Alzheimer's Disease Study (rrAD). Journal of Alzheimer's Disease, 2020, 77, 175-182.	1.2	4
262	Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS ONE, 2020, 15, e0237676.	1.1	20
263	No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study. Scientific Reports, 2020, 10, 13371.	1.6	7
264	Binding of omeprazole to protein targets identified by monoclonal antibodies. PLoS ONE, 2020, 15, e0239464.	1.1	9
265	Association between amphetamineâ€related disorders and dementiaâ€a nationwide cohort study in Taiwan. Annals of Clinical and Translational Neurology, 2020, 7, 1284-1295.	1.7	14
266	Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias. Scientific Reports, 2020, 10, 21046.	1.6	21
267	Comparative Evaluation and Management of Dysphonia Between Adults <65 and ≥65 Years of Age. Otolaryngology - Head and Neck Surgery, 2021, 165, 142-148.	1.1	5
268	Proton Pump Inhibitors and Incident <i>Clostridioides difficile</i> Infection: Beyond Controversy, Pragmatic Approaches Are Needed. Clinical Infectious Diseases, 2021, 72, e1090-e1092.	2.9	0
269	What is the truth about proton pump inhibitors?. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 376-384.	0.8	2
270	Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey. American Journal of Gastroenterology, 2020, 115, 689-696.	0.2	28
271	Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia. Alzheimer's and Dementia, 2020, 16, 1031-1042.	0.4	32

#	Article	IF	CITATIONS
272	Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Ecological Management and Restoration, 2020, 33, .	0.2	13
273	Laparoscopic Posterior Partial Fundoplication for Gastroesophageal Reflux Disease. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 642-648.	0.5	0
274	Long-term proton-pump inhibitor use in older adults with mild-to-moderate Alzheimer's disease: Are there cognitive consequences?. European Journal of Internal Medicine, 2020, 79, 114-117.	1.0	0
275	Association Between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study. Frontiers in Pharmacology, 2020, 11, 607.	1.6	17
276	How to advise patients on the risk of chronic proton pump inhibitor therapy. Current Opinion in Gastroenterology, 2020, 36, 317-322.	1.0	7
277	Latest insights into the hot question of proton pump inhibitor safety $\hat{a} \in \hat{a}$ a narrative review. Digestive and Liver Disease, 2020, 52, 842-852.	0.4	25
278	Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age and Ageing, 2020, 49, 939-947.	0.7	55
279	Proton Pump Inhibitor-Induced Galactorrhea in a Kidney Transplant Recipient: A Friend or Foe?. Case Reports in Transplantation, 2020, 2020, 1-5.	0.1	3
280	The Reflux Symptom Index and Symptom Overlap in Dysphonic Patients. Laryngoscope, 2020, 130, 2631-2636.	1.1	14
281	Side Effects of Proton Pump Inhibitors: What are Patients' Concerns?. Journal of Voice, 2021, 35, 809.e15-809.e20.	0.6	11
282	Is empirical treatment a reasonable strategy for laryngopharyngeal reflux? A contemporary review. Clinical Otolaryngology, 2020, 45, 450-458.	0.6	31
283	Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study. Journal of the American Geriatrics Society, 2020, 68, 746-753.	1.3	25
284	Proton Pump Inhibitors. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 239-251.	0.6	30
285	Proton Pump Inhibitors vs Histamine-2 Receptor Blockers for Stress Ulcer Prophylaxis in Critically III Patients. JAMA - Journal of the American Medical Association, 2020, 323, 611.	3.8	9
286	Cognitive problems of breast cancer survivors on proton pump inhibitors. Journal of Cancer Survivorship, 2020, 14, 226-234.	1.5	4
287	Increased risk of death associated with the use of protonâ€pump inhibitors in patients with dementia and controls – a pharmacoepidemiological claims data analysis. European Journal of Neurology, 2020, 27, 1422-1428.	1.7	3
288	Use of proton pump inhibitors is associated with lower rates of firstâ€time ischemic stroke in communityâ€dwelling elderly. British Journal of Clinical Pharmacology, 2021, 87, 1187-1193.	1.1	3
289	Esophageal and Gastric Motility Disorders in the Elderly. Clinics in Geriatric Medicine, 2021, 37, 1-16.	1.0	2

#	Article	IF	CITATIONS
290	Current Status of Chemoprevention in Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 117-130.	0.6	4
291	Multimorbidity networks of chronic obstructive pulmonary disease and heart failure in men and women: Evidence from the EpiChron Cohort. Mechanisms of Ageing and Development, 2021, 193, 111392.	2.2	12
292	Elevated anxiety, hypoactivity, memory deficits, decreases of brain serotonin and 5-HT-1A receptors expression in rats treated with omeprazole. Toxicological Research, 2021, 37, 237-248.	1.1	13
293	Ulcus-ventriculi- und Ulcus-duodeni-Krankheit. , 2021, , 62-75.		0
294	Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study. European Journal of Clinical Pharmacology, 2021, 77, 1039-1048.	0.8	5
295	Laryngopharyngeal Reflux. , 2021, , 89-101.		0
296	Minimally invasive fundoplication for gastroesophageal reflux disease. Annals of Esophagus, 0, .	0.4	0
297	Medication Management to Prevent and Mitigate Post-intensive Care Syndrome., 2021,, 173-183.		0
298	Cognition, oxidative stress and vitamin B12 levels evaluation on patients under long-term omeprazole use. Journal of Pharmacy and Pharmacology, 2022, 74, 547-555.	1.2	5
299	Drugs in Focus: Proton Pump Inhibitors. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 645-653.	0.9	13
300	Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital. European Journal of Hospital Pharmacy, 2022, 29, e30-e35.	0.5	12
301	The effects of proton pump inhibitors on neuropsychological functioning. Applied Neuropsychology Adult, 2021, , 1-10.	0.7	4
302	Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study. Respiratory Medicine, 2021, 178, 106309.	1.3	19
303	Low-dose PPI to prevent bleeding after ESD: A multicenter randomized controlled study. Biomedicine and Pharmacotherapy, 2021, 136, 111251.	2.5	5
305	Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between. Foregut, 2021, 1, 145-151.	0.3	1
306	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Scientific Reports, 2021, 11, 10709.	1.6	19
307	Lack of association between proton pump inhibitor use and decline in cognitive performance in the ELSA-Brasil cohort. European Journal of Clinical Pharmacology, 2021, 77, 1725-1735.	0.8	0
308	Proton-pump Inhibitors and the Risk of Dementia: A Systematic Review and Meta-analysis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2021, 21, 135-143.	0.1	2

#	Article	IF	CITATIONS
309	Association between Proton Pump Inhibitors and Hearing Impairment: A Nested Case-Control Study. Current Issues in Molecular Biology, 2021, 43, 142-152.	1.0	3
310	Perception of Proton Pump Inhibitor Side Effects Among Members of the American Broncho-Esophagological Association. Journal of Voice, 2021, , .	0.6	0
311	Promoting Successful Cognitive Aging: A Ten-Year Update. Journal of Alzheimer's Disease, 2021, 81, 871-920.	1.2	65
312	Protonâ€Pump Inhibitors. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 665-669.	0.9	4
313	Therapeutic prevention of COVID-19 in elderly: a case–control study. GeroScience, 2021, 43, 2333-2343.	2.1	12
314	CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 704583.	1.7	14
315	The gut microbiota and nervous system: Age-defined and age-defying. Seminars in Cell and Developmental Biology, 2021, 116, 98-107.	2.3	5
316	Changes in National Google Trends and Local Healthcare Utilization After High-Impact Gastroenterology Publications. American Journal of Gastroenterology, 2021, Publish Ahead of Print, .	0.2	0
317	An investigation of new medications initiation during ambulatory care visits in patients with dementia. Exploratory Research in Clinical and Social Pharmacy, 2021, 3, 100058.	0.6	0
318	Proton pump inhibitors long term useâ€trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiology and Drug Safety, 2021, 30, 1576-1587.	0.9	3
319	Development of Patient Education Material for Proton Pump Inhibitor Deprescribing: A Mixed-Methods Study. Annals of Pharmacotherapy, 2022, 56, 800-808.	0.9	3
320	The Janus-like Association between Proton Pump Inhibitors and Dementia. Current Alzheimer Research, 2021, 18, 453-469.	0.7	3
321	MangelernÃĦrung in der Gerontopsychiatrie. , 2021, , 115-124.		0
322	Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. European Journal of Clinical Pharmacology, 2017, 73, 1149-1158.	0.8	8
323	Sleep and Cognitive Impairment. , 2017, , 73-88.		1
324	Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients. Kidney International Reports, 2018, 3, 374-384.	0.4	25
325	Depression and anxiety with exposure to ozone and particulate matter: An epidemiological claims data analysis. International Journal of Hygiene and Environmental Health, 2020, 228, 113562.	2.1	34
327	Prescribing PPIs. Drug and Therapeutics Bulletin, 2017, 55, 117-120.	0.3	5

#	Article	IF	CITATIONS
328	Acid suppressants use and the risk of dementia:ÂA population-based propensity score-matched cohort study. PLoS ONE, 2020, 15, e0242975.	1.1	12
330	Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. Gastroenterology Research, 2019, 12, 305-311.	0.4	3
331	The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China. Revista Espanola De Enfermedades Digestivas, 2019, 111, 738-743.	0.1	16
332	Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist. Pharmacy Practice, 2016, 14, 868.	0.8	2
333	Chapter 13: Heartburn and Dyspepsia. , 2017, , .		2
334	Proton pump inhibitors and risk of dementia. Annals of Translational Medicine, 2016, 4, 240-240.	0.7	33
335	Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. Mini-Reviews in Medicinal Chemistry, 2020, 20, 975-987.	1.1	2
336	Perceptions of patient-centered care among Veterans with gastroesophageal reflux disease on proton pump inhibitor therapy. Patient Experience Journal, 2018, 5, 149-159.	0.3	1
337	Medication management in older adults. Cleveland Clinic Journal of Medicine, 2018, 85, 129-135.	0.6	11
338	Idiopathic pulmonary fibrosis: What primary care physicians need to know. Cleveland Clinic Journal of Medicine, 2018, 85, 377-386.	0.6	4
339	Proton pump inhibitors: More indigestion than relief?. Indian Journal of Nephrology, 2017, 27, 249.	0.2	8
340	Gastrointestinal Health., 2021,, 25-57.		O
341	Leukotriene Receptor Antagonist Use and Dementia Risk in Patients With Asthma: A Retrospective Cohort Study. In Vivo, 2021, 35, 3297-3303.	0.6	5
342	Proton Pump Inhibitor Prescribing and Monitoring Patterns Among Gastroenterology Practitioners. Journal of Clinical Gastroenterology, 2022, 56, 571-575.	1.1	2
343	Dexlansoprazol. Pharma-Kritik (discontinued), 2016, 37, .	0.0	0
344	MangelernÃ ¤ rung in der Gerontopsychiatrie. , 2017, , 221-229.		0
345	ĐĐ°Ñ†Ñ–Đ¾Đ½Đ°Đ»ÑŒĐ½Đ° ІĐΫĐΫ-Ñ,ĐμÑ€Đ°Đ¿Ñ–Ñ• Ñ€Đ,Đ∙Đ,ĐºĐ, Ñ,а Đ¿ĐμÑ€ĐμĐ²Đ°Đ³Đ, Ñ,Ñ€Đ,Đ²Đ	Ე° Ნ ℷ₳Đ³¼Đ	³Đ3⁄4 Đ∙аÑÑ
347	Using proton-pump inhibitors among hemodialysis patients - single academic dialysis center's preliminary experience. Progress in Health Sciences, 2017, 7, 39-43.	0.1	0

#	Article	IF	CITATIONS
348	Zuurbranden (pyrosis, refluxklachten)., 2018, , 283-290.		0
349	Proton Pump Inhibitors and Dementia - Clinical Judgment under Uncertainty. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	o
350	AlimentÃres System und Stoffwechsel. , 2018, , 13-70.		0
351	The Role of theÂPharmacist in Family Engagement in theÂIntensive Care Unit and During Transitions of Care. , 2018, , 301-314.		0
352	Current trends in the diagnosis and treatment of gastroesophageal reflux disease. Vnitrni Lekarstvi, 2018, 64, 588-594.	0.1	3
353	A Review on Complications of the Prolonged Use of Proton Pump Inhibitors (PPIs) and Presenting a Case of Barrett's Esophagus. Journal of Advanced Research in Medicine, 2018, 05, 14-24.	0.1	1
354	Geriatrics update 2018: Challenges in mental health, mobility, and postdischarge care. Cleveland Clinic Journal of Medicine, 2018, 85, 953-958.	0.6	1
355	Medical Management of LPR., 2019, , 59-73.		0
357	Cardiovascular Risk of Proton Pump Inhibitors. Methodist DeBakey Cardiovascular Journal, 2021, 15, 214.	0.5	19
358	Medical Treatment of GERD., 2020, , 121-143.		1
359	Determining proton pump inhibitor prescription dispensing patterns and adherence to STOPP criteria for Nova Scotia Seniors Pharmacare Program beneficiaries. Canadian Journal of Clinical Pharmacology, 2019, 26, e37-e51.	1.1	4
360	Omeprazole Prescription Habit. International Journal of Pharmaceutical Quality Assurance, 2021, 10, 578-582.	0.1	0
361	EFFICACY AND SAFETY OF THE COMPLEX PHYTO MEDICATION IN TREATMENT AND PREVENTION OF THE NSAID-INDUCED DAMAGES OF THE UPPER GASTROINTESTINAL TRACT IN OSTEOARTHRITIS PATIENTS. Bulletin of Problems Biology and Medicine, 2020, 4, 230.	0.0	0
362	Proton pump inhibitors reduce phlebotomy burden in patients with HFE-related hemochromatosis: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2021, 33, 1327-1331.	0.8	2
363	Does Alzheimer's disease stem in the gastrointestinal system?. Life Sciences, 2021, 287, 120088.	2.0	15
364	Beliefs about benefits and harms of medications and supplements for brain health. Preventive Medicine Reports, 2020, 17, 101060.	0.8	3
365	Deprescribing Inappropriate Proton Pump Inhibitors in a Family Medicine Residency Practice Office. PRIMER (Leawood, Kan), 2021, 5, 43.	0.6	4
366	The Possible Association Between Proton Pump Inhibitors and Dementia. Gastroenterology and Hepatology, 2016, 12, 644-646.	0.2	0

#	Article	IF	CITATIONS
367	PURLs: The benefits-and limits-of PPIs with warfarin regimens. Journal of Family Practice, 2017, 66, 694-696.	0.2	1
368	Evaluation of Prescribing Appropriateness and Initiatives to Improve Prescribing of Proton Pump Inhibitors at Vancouver General Hospital. Canadian Journal of Hospital Pharmacy, 2018, 71, 308-315.	0.1	3
369	Review of the Long-Term Effects of Proton Pump Inhibitors. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, 19-23.	0.6	0
370	Proton Pump Inhibitor Use and Risk of Dementia in the Veteran Population. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S27-S31.	0.6	5
371	No association between acid suppressant use and risk of dementia: an updated meta-analysis. European Journal of Clinical Pharmacology, 2022, 78, 375-382.	0.8	4
372	Effect of a Persian metabolic diet on the functional dyspepsia symptoms in patients with postprandial distress syndrome: a randomized, double-blind clinical trial. Journal of Complementary and Integrative Medicine, 2021, .	0.4	1
373	Proton Pump Inhibitors and Risk of Dementia: A Hypothesis Generated but Not Adequately Tested. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752110624.	0.9	2
374	Potentially inappropriate medications at discharge among elderly patients at a single tertiary emergency medical institution in Japan: a retrospective crossâ€sectional observational study. Acute Medicine & Surgery, 2021, 8, e711.	0.5	0
375	Latent Class Analysis of Prescribing Behavior of Primary Care Physicians in the Veterans Health Administration. Journal of General Internal Medicine, 2022, , 1.	1.3	3
376	Mechanistic Link between Vitamin B12 and Alzheimer's Disease. Biomolecules, 2022, 12, 129.	1.8	26
377	Gastric acid suppressants and cognitive decline in people with or without cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12243.	1.8	4
378	Drug Repurposing Patent Applications October: December 2021. Assay and Drug Development Technologies, 2022, , .	0.6	0
379	Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. Nature Aging, 2021, 1, 1175-1188.	5.3	87
380	Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. BMC Health Services Research, 2022, 22, 219.	0.9	6
381	Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers, 2022, 14, 1156.	1.7	6
382	Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study. Frontiers in Cardiovascular Medicine, 2022, 9, 767987.	1.1	12
383	Gastroesophageal Reflux in Children with Asthma. Children, 2022, 9, 336.	0.6	8
384	Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients. Renal Failure, 2022, 44, 407-414.	0.8	1

#	Article	IF	CITATIONS
385	AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology, 2022, 162, 1334-1342.	0.6	86
386	Chronic omeprazole use in the elderly is associated with decreased risk of dementia and cognitive decline. Digestive and Liver Disease, 2022, 54, 622-628.	0.4	6
387	Influence of Drugs on Mild Cognitive Impairment in Parkinson's Disease: Evidence from the PACOS Study. Current Neuropharmacology, 2021, 20, .	1.4	1
389	Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2671-e2679.	1.8	12
390	Proton pump inhibitors use and risk of incident nephrolithiasis. Urolithiasis, 2022, 50, 401-409.	1.2	4
391	Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130149.	1.1	1
392	SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS. Arquivos De Gastroenterologia, 2022, 59, 219-225.	0.3	9
393	Associations between proton pump inhibitors and Alzheimer's disease: a nested case–control study using a Korean nationwide health screening cohort. Alzheimer's Research and Therapy, 2022, 14, .	3.0	9
394	Assessment of Potentially Inappropriate Medications Using the EU (7)-PIM List, in a Sample of Portuguese Older Adults' Residents in Nursing Homes. Risk Management and Healthcare Policy, 0, Volume 15, 1343-1352.	1.2	4
395	Evaluation of proton pump inhibitor administration in hospitalized dogs in a tertiary referral hospital. Journal of Veterinary Internal Medicine, 2022, 36, 1622-1627.	0.6	5
396	Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. Lancet Rheumatology, The, 2022, 4, e795-e803.	2.2	6
397	A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer's disease and gastrointestinal tract disorders. Communications Biology, 2022, 5, .	2.0	45
398	DeclÃnio cognitivo e uso de medicamentos na população de idosos institucionalizados de uma cidade do interior de Minas Gerais, Brasil. Cadernos Saude Coletiva, 0, , .	0.2	1
399	Neuropsychological assessment after long-term omeprazole treatment. Applied Neuropsychology Adult, 0, , 1-9.	0.7	1
401	APPLICATION ANALYSIS OF DIGITAL NEURAL NETWORK-BASED DATA MINING METHOD IN MAXIMIZING THE PERFORMANCE OF SPORTS TRAINING. Revista Brasileira De Medicina Do Esporte, 0, 29, .	0.1	1
402	Proton pump inhibitor deprescription: A rapid review. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
403	Pharmacological Mechanism of Zuojin Pill for Gastroesophageal Reflux Disease: A Network Pharmacology Study. Journal of Food Quality, 2022, 2022, 1-13.	1.4	1
404	Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors. Journal of the Chinese Medical Association, 2022, 85, 915-921.	0.6	3

#	Article	IF	Citations
405	Regular proton pump inhibitor use and incident dementia: population-based cohort study. BMC Medicine, 2022, 20, .	2.3	9
406	Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database. Biological and Pharmaceutical Bulletin, 2022, 45, 1373-1377.	0.6	2
407	Signal and Noise: Proton Pump Inhibitors and the Risk of Dementia?. Clinical Pharmacology and Therapeutics, 2023, 113, 152-159.	2.3	1
408	Long-term use of proton-pump inhibitor on Alzheimer's disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211357.	1.5	0
409	Should I Be Concerned with the Long-Term Use of Proton Pump Inhibitor Therapy?. European Medical Journal Gastroenterology, 0, , 74-81.	0.0	0
410	Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Frontiers in Pharmacology, 0, 13, .	1.6	4
411	Do proton pump inhibitors increase the risk of dementia? A systematic review, metaâ€analysis and bias analysis. British Journal of Clinical Pharmacology, 2023, 89, 602-616.	1.1	5
412	Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study. Scientific Reports, 2022, 12, .	1.6	2
413	Proton pump inhibitors: Assessment of side effects and application in COVID-19 infection. Timocki Medicinski Glasnik, 2022, 47, 96-103.	0.0	0
415	Proton Pump Inhibitor Use and Cognitive Function in the Boston Puerto Rican Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	1.7	1
416	Use of proton pump inhibitor may be associated with progression of cerebral small vessel disease. PLoS ONE, 2022, 17, e0279257.	1.1	1
417	Potentially inadequate medications in the elderly: PRISCUS 2.0â€"first update of the PRISCUS list. Deutsches Ärzteblatt International, 0, , .	0.6	22
418	Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis. Archivio Italiano Di Urologia Andrologia, 2022, 94, 507-514.	0.4	1
419	New Edition of the EAEU Good Pharmacovigilance Practice: What Has Changed?. Safety and Risk of Pharmacotherapy, 2023, 11, 7-13.	0.1	0
420	Mechanistic Insight into the Inhibition of Choline Acetyltransferase by Proton Pump Inhibitors. ACS Chemical Neuroscience, 2023, 14, 749-765.	1.7	4
421	Laparoscopic Hiatal Hernia Repair With Concomitant Transoral Incisionless Fundoplication. AORN Journal, 2023, 117, 149-158.	0.2	0
422	Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Therapeutic Advances in Drug Safety, 2023, 14, 204209862311540.	1.0	4
423	Drug discovery: Chaos can be your friend or your enemy. , 2023, , 417-511.		2

#	Article	IF	CITATIONS
431	Proton pump inhibitor use: systematic review of global trends and practices. European Journal of Clinical Pharmacology, 2023, 79, 1159-1172.	0.8	11
454	Medical Therapy for Gastroesophageal Reflux Disease. , 2023, , 61-85.		0